New drug duo hopes to boost immune system against tough cancers
NCT ID NCT05238883
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for any tumor shrinkage, but this is a small, early study, so results are uncertain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HFB200301 (a drug that activates TNFR2) and tislelizumab (an anti-PD-1 antibody)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 72 participants, so the drug may not work or could have serious side effects. It is not yet known if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NEXT Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
The University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States